Chemoradiation-induced oral mucositis (CRIOM) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Oral mucositis is an important complication in non-surgical cancer treatments. It represents the major complication in radiotherapy of tumors located in head and neck areas. Mucositis manifests itself as erythema, edema, or ulceration that can be accompanied by a mild burning sensation. Radiation-induced mucositis may involve any radiation-exposed area, including the hard palate, lip, buccal mucosa, tongue ventrolateral aspect, and base of the mouth. The direct mechanisms of irradiation include interrupting the cell renewal cycle and apoptosis. The indirect mechanisms leading to oral mucositis include the release of inflammation mediators, the loss of protective salivary role, and neutropenia induced by the treatment.
· Oropharyngeal
mucositis occurs in more than 85 to 92% of patients who receive radiation and
or chemotherapy for head and neck tumors.
· According
to the research, ~85% of patients undergoing radiation therapy showed
oropharyngeal mucositis amongst which ~30% developed severe oropharyngeal
mucositis.
The competitive
landscape of Chemoradiation-induced oral mucositis (CRIOM) includes country-specific
approved and pipeline therapies. Any asset/product-specific designation or
review and Accelerated Approval are tracked and supplemented with analyst
commentary.
KOLs insights of Chemoradiation-induced
oral mucositis (CRIOM) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Chemoradiation-induced
oral mucositis (CRIOM) Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 EC-18 Enzychem
Lifesciences Phase 2
Comments
Post a Comment